Sapacitabine(CAS: 151823-14-2)

Sapacitabine (CAS: 151823-14-2) falls under the regulatory guidelines of the Chemicals in the European Union (REACH) and the United States Environmental Protection Agency (EPA). For pharmaceutical purposes, it also adheres to FDA requirements for drug substances and products. It is recommended to consult the latest GHS (Globally Harmonized System of Classification and Labeling of Chemicals) for accurate hazard classification and labeling.

While Sapacitabine (CAS: 151823-14-2) is a specific and effective drug, alternatives in terms of nucleoside analogs for similar biological activity include other cytidine analogs such as clofarabine and fludarabine. These can serve as substitutes depending on the specific synthesis route and desired properties.

Sapacitabine (CAS: 151823-14-2) is primarily used in oncology for the treatment of acute myeloid leukemia. Market trends indicate increasing research interest in its efficacy and safety, particularly in combination therapies. Studies are also exploring its potential in other hematological cancers. The trend suggests a steady market demand with ongoing clinical trials.

Waste containing Sapacitabine (CAS: 151823-14-2) should be collected in appropriate containers and stored separately. For disposal, it is recommended to follow local hazardous waste regulations, which may include incineration or professional waste disposal services. Ensure all disposal methods comply with REACH and GHS guidelines to minimize environmental impact and ensure safety during handling and transportation.